1 – 29 of 29
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
A comparative study of fatigue and processing speed in patients with multiple sclerosis treated with natalizumab or rituximab
(
- Contribution to journal › Article
-
Mark
EULAR recommendations for the management of ANCA-associated vasculitis : 2022 update
(
- Contribution to journal › Article
- 2023
-
Mark
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
(
- Contribution to journal › Article
- 2022
-
Mark
Severe infections in patients with ANCA-associated vasculitis treated with rituximab
(
- Contribution to journal › Article
-
Mark
The management of membranous nephropathy—an update
(
- Contribution to journal › Article
-
Mark
Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases : consensus statements from the ERA-IWG and EUVAS
(
- Contribution to journal › Scientific review
- 2021
-
Mark
Rituximab in Membranous Nephropathy
(
- Contribution to journal › Scientific review
- 2020
-
Mark
Monitoring of the Complement System Status in Patients With B-Cell Malignancies Treated With Rituximab
(
- Contribution to journal › Article
-
Mark
Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?
(
- Contribution to journal › Scientific review
-
Mark
Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients
(
- Contribution to journal › Article
- 2019
-
Mark
Mutations resulting in the formation of hyperactive complement convertases support cytocidal effect of anti-CD20 immunotherapeutics
(
- Contribution to journal › Article
-
Mark
Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice : A prospective cohort study
(
- Contribution to journal › Article
-
Mark
Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis
(
- Contribution to journal › Article
-
Mark
Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA : Results from the nationwide Swedish register
(
- Contribution to journal › Article
- 2018
-
Mark
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Mantle cell lymphoma strategies in primary treatment
(
- Thesis › Doctoral thesis (compilation)
- 2017
-
Mark
Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014 : An analysis of the Swedish Lymphoma Registry
(
- Contribution to journal › Article
-
Mark
Rituximab in clinical practice : dosage, drug adherence, Ig levels, infections, and drug antibodies
(
- Contribution to journal › Article
- 2016
-
Mark
Burkitt lymphoma and diffuse large B-cell lymphoma – therapeutic strategies and pathogenetic mechanisms
2016)(
- Thesis › Doctoral thesis (compilation)
-
Mark
Rituximab for treatment of severe renal disease in ANCA associated vasculitis
(
- Contribution to journal › Article
- 2014
-
Mark
Immunosuppressive agents in the treatment of inhibitors in congenital haemophilia A and B - a systematic literature review
(
- Contribution to journal › Scientific review
- 2012
-
Mark
CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group
(
- Contribution to journal › Article
-
Mark
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC plus autologous stem-cell support: still very long survival but late relapses do occur
(
- Contribution to journal › Article
- 2009
-
Mark
Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden
(
- Contribution to journal › Article
-
Mark
A Randomized, Doubleblind, Placebo-Controlled, Study of Single-Dose Rituximab as Induction in Renal Transplantation
(
- Contribution to journal › Article
- 2008
-
Mark
Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group
(
- Contribution to journal › Article
-
Mark
Fludarabine, cyclophosphamide and rituximab (FCR) induced pulmonary hypertension in Waldenstrom macroglobulinemia
(
- Contribution to journal › Article
- 2007
-
Mark
Parametric images of antibody pharmacokinetics based on serial quantitative whole-body imaging and blood sampling
(
- Contribution to journal › Article
- 2006
-
Mark
Heart transplantation across the antibodies against HLA and ABO
(
- Contribution to journal › Article